[go: up one dir, main page]

BRPI0822909B8 - sal de glicinato de metformina para o controle da glicose sanguínea - Google Patents

sal de glicinato de metformina para o controle da glicose sanguínea

Info

Publication number
BRPI0822909B8
BRPI0822909B8 BRPI0822909A BRPI0822909A BRPI0822909B8 BR PI0822909 B8 BRPI0822909 B8 BR PI0822909B8 BR PI0822909 A BRPI0822909 A BR PI0822909A BR PI0822909 A BRPI0822909 A BR PI0822909A BR PI0822909 B8 BRPI0822909 B8 BR PI0822909B8
Authority
BR
Brazil
Prior art keywords
metformin
salt
glycine
glycinate
exhibits
Prior art date
Application number
BRPI0822909A
Other languages
English (en)
Inventor
Manuel Francisco Lara Ochoa Jose
Original Assignee
Laboratorios Silanes S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0822909(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Silanes S A De C V filed Critical Laboratorios Silanes S A De C V
Publication of BRPI0822909A2 publication Critical patent/BRPI0822909A2/pt
Publication of BRPI0822909B1 publication Critical patent/BRPI0822909B1/pt
Publication of BRPI0822909B8 publication Critical patent/BRPI0822909B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

sal de glicinato de metformina para o controle de glicose sanguínea nesta invenção, um novo sal e 1,1-dimetilbiguanida giicinato foi sintetiza-do, chamado de glicinato de metformina. este sal exibe vantagens sobre os outros sais de metformina. estas vantagens são, em primeiro lugar, devidas ao fato de que o contra-íon de glicina exibe efeitos hipoglicêmicos por si próprio. além disso, este sal 10 exibe absorção mais rápida, alcançando concentrações de plasma mais altas que aquelas produzidas com hidrocloreto de metformina. a síntese foi sintetizada a partir de sal de hidrocloreto de metformina, onde a metformina livre foi produzida através da liberação do contra-íon do hidroclorato, com o uso de uma coluna de troca de íon para este propósito; a base de metformina liberação foi dissolvida em um meio aquoso e, subsequentemente, a glicina foi adicionada à temperatura ambiente sob agitação constante; subsequentemente, o produto resultante é aquecido até que uma solução concentrada seja produzida, um solvente orgânico é adicionado, q qual não reage com os componentes presentes e sendo que a glicina é insolúvel a fim de criar isolabilidade no meio e favorecer a cristalização do meio saturado; tudo isto com a finalidade de precipitar o excesso de glicina e, então, separar isto através da filtração; sendo que o filtrado foi concentrado novamente até que a precipitação do sal de glicinato de metformina fosse alcançada.
BRPI0822909A 2008-06-26 2008-06-26 sal de glicinato de metformina para o controle da glicose sanguínea BRPI0822909B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/002665 WO2009144527A1 (en) 2008-06-26 2008-06-26 A new metformin glycinate salt for blood glucose control

Publications (3)

Publication Number Publication Date
BRPI0822909A2 BRPI0822909A2 (pt) 2015-06-30
BRPI0822909B1 BRPI0822909B1 (pt) 2019-11-12
BRPI0822909B8 true BRPI0822909B8 (pt) 2021-05-25

Family

ID=40383805

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822909A BRPI0822909B8 (pt) 2008-06-26 2008-06-26 sal de glicinato de metformina para o controle da glicose sanguínea

Country Status (26)

Country Link
US (2) US8703183B2 (pt)
EP (1) EP2303838B1 (pt)
JP (1) JP5551691B2 (pt)
KR (1) KR101522066B1 (pt)
CN (1) CN102159539B (pt)
AR (1) AR074159A1 (pt)
AU (1) AU2008357111B2 (pt)
BR (1) BRPI0822909B8 (pt)
CA (1) CA2729035C (pt)
CL (1) CL2009001484A1 (pt)
CY (1) CY1115098T1 (pt)
DK (1) DK2303838T3 (pt)
EC (1) ECSP10010719A (pt)
ES (1) ES2450148T3 (pt)
HR (1) HRP20140194T1 (pt)
JO (1) JO2884B1 (pt)
MA (1) MA32418B1 (pt)
MX (1) MX2011000135A (pt)
NI (1) NI201000234A (pt)
PE (1) PE20100257A1 (pt)
PL (1) PL2303838T3 (pt)
PT (1) PT2303838E (pt)
SI (1) SI2303838T1 (pt)
TN (2) TN2010000604A1 (pt)
UY (1) UY31945A (pt)
WO (1) WO2009144527A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2303838B1 (en) 2008-06-26 2013-12-04 Laboratorios Silanes, S.A. de C.V. A new metformin glycinate salt for blood glucose control
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
CN103263405B (zh) * 2013-05-08 2015-04-22 南京医科大学 用于治疗糖尿病的药物组合物及其应用
WO2015042495A2 (en) * 2013-09-22 2015-03-26 Jiva Pharma, Inc. Metformin salts to treat type2 diabetes
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
BR112016029476A2 (pt) 2014-06-18 2017-08-22 Thetis Pharmaceuticals Llc complexos de aminoácido mineral de agentes ativos
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
CA2927335C (en) 2014-10-27 2023-05-02 Aseko, Inc. Subcutaneous outpatient management
CN105030745A (zh) * 2015-07-08 2015-11-11 南京医科大学 甘氨酸和二甲双胍的酰胺化产物在制备治疗糖尿病药物中的应用
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
MX2019003725A (es) * 2016-09-30 2019-08-12 Laboratorios Silanes S A De C V Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma.
WO2018060962A2 (en) 2016-09-30 2018-04-05 Laboratorios Silanes S.A. De C.V. Metformin amino acid compounds and methods of using the same
CN113105367B (zh) * 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用
CN114349665B (zh) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE568513A (pt)
FR2037002A1 (en) 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
DE1967138A1 (de) 1969-07-17 1977-11-10 Christian Brunnengraeber Chem Therapeutisches mittel
AT325632B (de) 1973-06-01 1975-10-27 Hurka Wilhelm Verfahren zur herstellung von nicotinsauren salzen von derivaten des biguanids
FR2243684B1 (pt) 1973-09-19 1977-01-28 Semb
CH602612A5 (pt) 1974-10-11 1978-07-31 Hoffmann La Roche
FR2320735A1 (fr) 1975-08-12 1977-03-11 Dabis Georges Composition anti-cellulite
JPS57179494A (en) 1981-04-30 1982-11-05 Mitsubishi Plastics Ind Method of closing through hole of pipe, circumferential wall thereof has through hole in pipe axial direction
FR2585572B3 (fr) 1985-07-31 1987-12-31 Hugelin Andre Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
PT793646E (pt) * 1994-11-23 2002-03-28 Biovitrum Ab Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente
DE69822505T2 (de) 1997-12-08 2005-01-20 Bristol-Myers Squibb Co. Neue metformin-salze und verfahren
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
US20030220301A1 (en) * 2002-02-14 2003-11-27 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US7181457B2 (en) * 2003-05-28 2007-02-20 Pervasive Software, Inc. System and method for utilizing compression in database caches to facilitate access to database information
CA2543181A1 (en) 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
WO2005065675A1 (en) * 2004-01-07 2005-07-21 Premacs International Pty. Ltd. Method of treatment
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
WO2006113978A2 (en) * 2005-04-27 2006-11-02 Jallal Messadek Insulins combinations
CN101522658A (zh) * 2006-06-16 2009-09-02 因迪基恩药物公司 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐
NZ556735A (en) * 2007-07-24 2009-03-31 Vector Ltd Securing devices and equipotential bonding system
EP2303838B1 (en) 2008-06-26 2013-12-04 Laboratorios Silanes, S.A. de C.V. A new metformin glycinate salt for blood glucose control

Also Published As

Publication number Publication date
JP5551691B2 (ja) 2014-07-16
CY1115098T1 (el) 2016-12-14
PE20100257A1 (es) 2010-04-10
JO2884B1 (en) 2015-03-15
MA32418B1 (fr) 2011-06-01
KR20110042165A (ko) 2011-04-25
DK2303838T3 (en) 2014-03-03
KR101522066B1 (ko) 2015-05-20
BRPI0822909A2 (pt) 2015-06-30
PT2303838E (pt) 2014-03-10
TN2010000607A1 (en) 2012-05-24
ECSP10010719A (es) 2011-01-31
TN2010000604A1 (en) 2012-05-24
USRE46496E1 (en) 2017-08-01
MX2011000135A (es) 2011-02-25
SI2303838T1 (sl) 2014-07-31
WO2009144527A1 (en) 2009-12-03
AR074159A1 (es) 2010-12-29
CA2729035C (en) 2015-10-20
HRP20140194T1 (hr) 2014-06-20
UY31945A (es) 2010-01-05
JP2011525900A (ja) 2011-09-29
NI201000234A (es) 2012-03-19
US20110171142A1 (en) 2011-07-14
CA2729035A1 (en) 2009-12-03
EP2303838B1 (en) 2013-12-04
AU2008357111B2 (en) 2013-05-09
US8703183B2 (en) 2014-04-22
CN102159539B (zh) 2014-04-16
AU2008357111A1 (en) 2009-12-03
ES2450148T3 (es) 2014-03-24
CL2009001484A1 (es) 2009-12-04
BRPI0822909B1 (pt) 2019-11-12
EP2303838A1 (en) 2011-04-06
PL2303838T3 (pl) 2014-07-31
CN102159539A (zh) 2011-08-17

Similar Documents

Publication Publication Date Title
BRPI0822909B8 (pt) sal de glicinato de metformina para o controle da glicose sanguínea
ES2728247T3 (es) Método para la preparación cíclica de taurina a partir de una sal de metal alcalino de ácido hidroxietil sulfónico y una sal de metal alcalino de ácido vinil sulfónico
ES2655681T3 (es) Membrana polimérica funcional y método para su producción
BR112015000373A2 (pt) metódo para produzir composto de politiol, composição polimerizável para material ótico e usos dos mesmos
BR112015000088A2 (pt) composições farmacêuticas compreendendo rifamixinaa e aminoácidos, método de preparação e uso das mesmas
BR0313178A (pt) Derivados de pirazol e processo para a produção destes
AR062134A1 (es) Erlotinib cristalino
BR112018012106A2 (pt) forma cristalina de inibidor de btk quinase e método de preparação da mesma
BR112017015032A2 (pt) composições curáveis e membranas
EA200500420A1 (ru) Бензолсульфонатные соли производных 4-фтор-2-цианопирролидина
BR112017023714A2 (pt) processo para preparação de polímeros à base de dimetiltaurato de acriloíla e monômeros neutros
BR112017018580A2 (pt) p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal
CO6290754A2 (es) Método para producir bicarbonato de arginina
BRPI0509595B8 (pt) processos para a preparação de cristais de forma a e de material de padrão c de bissulfato de atazanavir
BRPI0720465A2 (pt) Processo para produção de composto de precursor para composto orgânico marcado com halogênio radioativo
BR112013024082B1 (pt) composto e composição de agente branqueador fluorescente, seus usos e processo para branqueamento e papel obtido no referido processo
RU2005138590A (ru) Фармацевтически полезные соли производных карбоновой кислоты
AR047544A1 (es) Proceso para la preparacion de compuestos de triazol sustituidos
AR057022A1 (es) Proceso para resolver un r o s acido mandelico a partir de su mezcla racemica
BR102020011608A2 (pt) Processo de produção de n-acetil taurinato de magnésio e seu produto obtido
RU2006109914A (ru) Способ получения супрамолекулярного геля
RU2013106503A (ru) Способ получения контрастных агентов
DE602007013796D1 (de) Ausstossflüssigkeit und ausstossverfahren
DK2234974T3 (da) Fremgangsmåde til fremstilling af (S)-1-alkyl-2',6'-pipecoloxylidid-forbindelse
AR036018A1 (es) Proceso para aislar monohidrato de imipenem cristalino puro

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: LABORATORIOS SILANES S.A. DE C.V. (MX)